Summary
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers and new product offerings that require advanced drug delivery. Pulmonary drug delivery offers the potential for noninvasive administration of a wide variety of macromolecules. Nearly every biotherapeutic product that treats chronic or long-term illness would benefit from noninvasive delivery by providing a competitive advantage with current therapeutics. This advantage could expand the market for each product or enable new indications to be considered. Kalorama's Drug Delivery Markets. Edition 2 Volume III: Pulmonary Delivery Systems, the third volume of Kalorama's popular series focusing on global drug delivery systems markets, provides the definitive break down of the market for pulmonary delivery system markets. The report covers both pharmaceuticals sold through pulmonary delivery systems and the technologies themselves. The report provides current market size and revenue for the following main categories: - Inhalation drug delivery
- Intranasal drug delivery
- Kalorama believes the future of drug administration by inhalation will expand vastly and be a significant driver in this market. Serious market-watchers who are looking at new products or ways to expand existing products will find this information essential.
As part of its comprehensive cooverage, Kalorama's report includes: - A Breakdown of Demographics and Trends that will drive pulmonary delivery.
- New Developments including Prodrug Technology, Electrohydrodynamic
- Aerosol Delivery, Oxygen Delivery and Crystallization Technology
- Detailed Discussion of Current Products in pulmonary drug delivery.
- Current Market Size and Forecasts to 2010.
- Review of Pipleline products
- Profiles of Key Companies in the Pulmonary Delivery markets.
- As part of Kalorama's trusted information-gathering process, industry executives are consulted. While government and company data is culled, it is interviews with executives that provide the foundation for market sizes and forecasts.
Kalorama's coverage of the pulmonary drug delivery market includes coverage of the following companies in this field: - 3M
- Alkermes
- Aradigm
- Elan
- Nastech
- Nektar
- SkyePharma
|
